Annika Lindsten
Overview
Explore the profile of Annika Lindsten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Areberg J, Rosen M, Lindsten A, Dragheim M, Ryding J
Basic Clin Pharmacol Toxicol
. 2024 Aug;
135(4):512-522.
PMID: 39206528
This population pharmacokinetics (PopPK) analysis of eptinezumab used data from a paediatric study and a prior adult PopPK model to compare eptinezumab pharmacokinetics between adult and paediatric populations to determine...
2.
Ailani J, McAllister P, Winner P, Chakhava G, Josiassen M, Lindsten A, et al.
BMC Neurol
. 2023 Sep;
23(1):318.
PMID: 37674117
No abstract available.
3.
Cady R, Lipton R, Buse D, Josiassen M, Lindsten A, Ettrup A
J Headache Pain
. 2022 Jul;
23(1):91.
PMID: 35902796
Background: The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute...
4.
Ailani J, McAllister P, Winner P, Chakhava G, Josiassen M, Lindsten A, et al.
BMC Neurol
. 2022 Jun;
22(1):205.
PMID: 35659622
Background: Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache...
5.
McAllister P, Winner P, Ailani J, Buse D, Lipton R, Chakhava G, et al.
J Headache Pain
. 2022 Feb;
23(1):22.
PMID: 35130832
Background: Demonstrating therapeutic value from the patient perspective is important in patient-centered migraine management. The objective of this study was to investigate the impact of eptinezumab, a preventive migraine treatment,...
6.
Hauser R, Favit A, Hewitt L, Lindsten A, Gorny S, Kymes S, et al.
Neurol Ther
. 2022 Feb;
11(1):459-469.
PMID: 35107750
Introduction: Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa...
7.
Winner P, McAllister P, Chakhava G, Ailani J, Ettrup A, Josiassen M, et al.
JAMA
. 2021 Jun;
325(23):2348-2356.
PMID: 34128999
Importance: Intravenous eptinezumab, an anti-calcitonin gene-related peptide antibody, is approved for migraine prevention in adults. It has established onset of preventive efficacy on day 1 after infusion. Objective: To evaluate...
8.
Hewitt L, Lindsten A, Gorny S, Karnik-Henry M, Kymes S, Favit A
Health Sci Rep
. 2021 Feb;
4(1):e227.
PMID: 33521332
Background And Aims: Patients with neurogenic orthostatic hypotension (nOH) due to autonomic dysfunction may also experience supine hypertension (defined as supine systolic blood pressure [SBP] ≥140 mmHg). Because pressor agents...
9.
Krystal A, Mittoux A, Lindsten A, Baker R
J Affect Disord
. 2020 Sep;
278:288-295.
PMID: 32979560
Background: Circadian rhythm disturbances have been reported in patients with major depressive disorder (MDD). Among these is an increased phase angle between peak cortisol concentration and dim-light melatonin onset (DLMO)....
10.
Biederman J, Lindsten A, Sluth L, Petersen M, Ettrup A, Eriksen H, et al.
J Psychopharmacol
. 2019 Mar;
33(4):511-521.
PMID: 30843450
Background: Stimulants remain the mainstay of treatment for attention-deficit hyperactivity disorder (ADHD) but are often associated with insufficient response or poor tolerability, leading to many patients not wishing to be...